Literature DB >> 11496143

Delayed application of IGF-I and GDNF can rescue already injured postnatal motor neurons.

M M Bilak1, R W Kuncl.   

Abstract

IGF-I, GDNF, and other neurotrophic factors, when applied at the time of injury, can protect postnatal motor neurons from slow glutamate injury in organotypic spinal cord. However, in human spinal cord diseases, motor neuron injury is already established when treatment could begin. We tested whether neurotrophic factors can protect already-injured motor neurons, and whether combinations of factors can further lengthen the therapeutic time window. Our data show that during a 7--8 week process of slow neurodegeneration either IGF-I or GDNF treatment, though delayed up to 4 weeks, still allowed substantial rescue of already injured motor neurons. However, the combination of both factors additively provided better neuroprotection than either factor alone, even after a 4-week delay. This proof of principle is relevant to the potential of IGF-I and GDNF as therapy for acquired disorders affecting motor neurons.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11496143     DOI: 10.1097/00001756-200108080-00048

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  13 in total

1.  Adeno-associated viral-mediated insulin-like growth factor delivery protects motor neurons in vitro.

Authors:  Andrea M Vincent; Eva L Feldman; Debbie K Song; Verena Jung; Andreas Schild; Wei Zhang; Michael J Imperiale; Nicholas M Boulis
Journal:  Neuromolecular Med       Date:  2004       Impact factor: 3.843

Review 2.  Insulin-like growth factors in the peripheral nervous system.

Authors:  Kelli A Sullivan; Bhumsoo Kim; Eva L Feldman
Journal:  Endocrinology       Date:  2008-08-21       Impact factor: 4.736

3.  Optimized methods for rapidly dissecting spinal cords and harvesting spinal motor neurons with high survival and purity from rats at different embryonic stages.

Authors:  Shudong Chen; Ruimin Tian; Hui Li; Meihui Chen; Hu Zhang; Dingkun Lin
Journal:  J Spinal Cord Med       Date:  2017-05-25       Impact factor: 1.985

Review 4.  Dysregulation of IGF-1/GLP-1 signaling in the progression of ALS: potential target activators and influences on neurological dysfunctions.

Authors:  Ambika Shandilya; Sidharth Mehan
Journal:  Neurol Sci       Date:  2021-05-21       Impact factor: 3.307

5.  Culture of motor neurons from newborn rat spinal cord.

Authors:  Shigang Cheng; Ying Shi; Bo Hai; Xiaomin Han; Zhaohui Chen; Bing Li; Chuanguo Xiao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-08-07

6.  The association between cancer and amyotrophic lateral sclerosis.

Authors:  D Michal Freedman; Rochelle E Curtis; Sarah E Daugherty; James J Goedert; Ralph W Kuncl; Margaret A Tucker
Journal:  Cancer Causes Control       Date:  2012-10-23       Impact factor: 2.506

7.  Intraparenchymal spinal cord delivery of adeno-associated virus IGF-1 is protective in the SOD1G93A model of ALS.

Authors:  Angelo C Lepore; Christine Haenggeli; Mehdi Gasmi; Kathie M Bishop; Raymond T Bartus; Nicholas J Maragakis; Jeffrey D Rothstein
Journal:  Brain Res       Date:  2007-09-22       Impact factor: 3.252

8.  IGF-I gene delivery promotes corticospinal neuronal survival but not regeneration after adult CNS injury.

Authors:  Edmund R Hollis; Paul Lu; Armin Blesch; Mark H Tuszynski
Journal:  Exp Neurol       Date:  2008-10-02       Impact factor: 5.330

Review 9.  Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis.

Authors:  Stacey A Sakowski; Adam D Schuyler; Eva L Feldman
Journal:  Amyotroph Lateral Scler       Date:  2009-04

10.  Artemin, a member of the glial cell line-derived neurotrophic factor family of ligands, is HER2-regulated and mediates acquired trastuzumab resistance by promoting cancer stem cell-like behavior in mammary carcinoma cells.

Authors:  Keshuo Ding; Arindam Banerjee; Sheng Tan; JunSong Zhao; Qian Zhuang; Rui Li; Pengxu Qian; Suling Liu; Zheng-Sheng Wu; Peter E Lobie; Tao Zhu
Journal:  J Biol Chem       Date:  2014-04-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.